OpenEvidence and iatroX represent two genuinely different philosophies for building trust into a clinical AI answer, and comparing them fairly means being precise about what each is actually optimising for, rather than treating them as competing on identical terms.
The core question each platform is answering
OpenEvidence's EvidenceGrade is built to answer: how certain is the published evidence behind this specific answer. iatroX's approach is built to answer a related but distinct question: what is the best-supported and UK-relevant answer for this specific clinical question, given the available evidence and current guidance together.
The genuine strengths of automated grading
Automated, real-time grading is fast, visible at a glance, and scalable across the enormous volume of everyday clinical questions that would never otherwise receive any formal evidence appraisal at all. It can alert a clinician to genuinely limited evidence behind an answer that might otherwise read as confidently as any other.
The genuine limitations of automated grading
The same approach carries real risk of false precision, a clean letter grade implying more certainty about the grading process itself than the underlying methodology can fully support. Combining heterogeneous studies into a single assessment remains genuinely difficult, as covered in detail elsewhere in this cluster. Multi-claim answers risk being oversimplified into one grade that does not represent every claim within them equally well. And the whole approach is necessarily dependent on whatever corpus the retrieval system actually surfaces, which may not always be the most complete or most relevant possible set.
The genuine strengths of hierarchical source prioritisation
Starting from evidence most likely to be reliable, rather than grading whatever happens to be retrieved after the fact, avoids treating every citation as equally worth considering in the first place. This approach aligns naturally with how evidence-based medicine has always been taught and practised, prioritisation at the point of selection rather than assessment after collection.
The genuine limitations of hierarchical prioritisation
Hierarchy alone does not establish the quality of any specific study within its category, a point covered directly elsewhere in this cluster. A meta-analysis, despite sitting near the top of the hierarchy, can still be poor. And a guideline, despite its authority, can become outdated if new evidence has emerged since its last review.
iatroX as a genuinely distinct alternative, not an imitation
iatroX is a UK and EU clinician-founded platform built around a different starting philosophy, not an attempt to replicate OpenEvidence's specific feature set under a different name. The two products are solving overlapping but distinct problems, for substantially different primary audiences.
Scenario-based recommendations, not a single verdict
For a US-based clinician wanting rapid synthesis of the latest published literature with visible evidence-strength grading, OpenEvidence is a strong fit for that specific need. For a UK-based clinician wanting an answer already filtered through NICE, CKS and NHS-relevant guidance, with the underlying evidence hierarchy informing what gets surfaced in the first place, iatroX is the more directly useful tool. Declaring one universally superior misses that they are, in important respects, built for different questions.
Why the comparison itself is a useful exercise, even without a winner
Setting these two platforms side by side is valuable precisely because it clarifies what each is actually optimising for, which is often obscured when a product is evaluated in isolation. A feature that looks like a weakness in isolation, iatroX not offering claim-level automated grading, or OpenEvidence not building in UK guideline concordance, looks more like a deliberate scope decision once the comparison makes each platform's core question explicit. Clinicians choosing between tools are better served understanding this kind of scope difference than searching for a single, universal ranking that neither platform is actually competing to win.